Neurobiological effects of hyperforin and its potential in Alzheimer's disease therapy

Current Medicinal Chemistry

Volumn 17, Issue 5, 2010, Pages 391-406

  Griffith, T N ^a   Varela Nallar, L ^a   Dinamarca, M C ^a   Inestrosa, N C ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Alzheimer's transgenic mice; Amyloid aggregates; NMDA receptors; St. John's Wort; TRPC6 channels

Indexed keywords

AMILORIDE; AMYLOID BETA PROTEIN; CATION CHANNEL; HYPERFORIN; HYPERICUM PERFORATUM EXTRACT; IDN 5706; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROPROTECTIVE AGENT; NEUROTRANSMITTER; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN LEVEL; COGNITION; DRUG ACTIVITY; DRUG EFFECT; HUMAN; IC 50; LEARNING; MEMORY; MEMORY DISORDER; NEUROBIOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; REVIEW; SINGLE DRUG DOSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIDEPRESSIVE AGENTS; BICYCLO COMPOUNDS; COGNITION DISORDERS; HYPERICUM; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PHLOROGLUCINOL; RECEPTORS, N-METHYL-D-ASPARTATE; TERPENES; TRPC CATION CHANNELS;

EID: 77950671885     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790226156     Document Type: Review

References (175)

1. Capasso, L. 5300 years ago, the Ice Man used natural laxatives and antibiotics. Lancet, 1998, 352, 1864. (Pubitemid 28550101)
2. De Vry, J.; Maurel, S.; Schreiber, R.; de Beun, R.; Jentzsch, K.R. Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism. Eur. Neuropsychopharmacol., 1999, 9, 461-468.
3. Schulz, V. Clinical trials with hypericum extracts in patients with depression - results, comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine, 2002, 9, 468-474.
4. Butterweck, V.; Nahrstedt, A. [What is known about St. John's wort? Phytochemistry and pharmacology]. Pharm. Unserer. Zeit., 2003, 32, 212-219.
5. Muller, W.E. Current St John's wort research from mode of action to clinical efficacy. Pharmacol. Res., 2003, 47, 101-109.
6. Miller, A.L. St. John's Wort (Hypericum perforatum): clinical effects on depression and other conditions. Altern. Med. Rev., 1998, 3, 18-26.
7. Wagner, H.; Bladt, S. Pharmaceutical quality of hypericum extracts. J. Geriatr. Psychiatry Neurol., 1994, 7 Suppl 1, S65-68.
8. Nahrstedt, A.; Butterweck, V. Biologically active and other chemical constituents of the herb of Hypericum perforatum L. Pharmacopsychiatry, 1997, 30 Suppl 2, 129-134. (Pubitemid 27414453)
9. Butterweck, V.; Schmidt, M. St. John's wort: role of active compounds for its mechanism of action and efficacy. Wien. Med. Wochenschr. (1946)., 2007, 157, 356-361.
10. Harrison, P. Herbal medicine takes root in Germany. CMAJ, 1998, 158, 637-639. (Pubitemid 28138345)
11. Volz, H.P. Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry, 1997, 30 Suppl 2, 72-76. (Pubitemid 27414442)
12. Philipp, M.; Kohnen, R.; Hiller, K.O. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ, 1999, 319, 1534-1538.
13. Brenner, R.; Azbel, V.; Madhusoodanan, S.; Pawlowska, M. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin. Ther., 2000, 22, 411-419. (Pubitemid 30304793)
14. Woelk, H. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. BMJ, 2000, 321, 536-539.
15. Bilia, A.R.; Gallori, S.; Vincieri, F.F. St. John's wort and depression: efficacy, safety and tolerability-an update. Life Sci., 2002, 70, 3077-3096. (Pubitemid 34464135)
16. Shelton, R.C.; Keller, M.B.; Gelenberg, A.; Dunner, D.L.; Hirschfeld, R.; Thase, M.E.; Russell, J.; Lydiard, R.B.; Crits-Cristoph, P.; Gallop, R.; Todd, L.; Hellerstein, D.; Goodnick, P.; Keitner, G.; Stahl, S.M.; Halbreich, U. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA, 2001, 285, 1978-1986. (Pubitemid 32366950)
17. Suzuki, O.; Katsumata, Y.; Oya, M.; Bladt, S.; Wagner, H. Inhibition of monoamine oxidase by hypericin. Planta Med., 1984, 50, 272-274.
18. Thiede, H.M.; Walper, A. Inhibition of MAO and COMT by hypericum extracts and hypericin. . J. Geriatr. Psychiatry. Neurol., 1994, 7 Suppl 1, S54-56.
19. Bladt, S.; Wagner, H. Inhibition of MAO by fractions and constituents of hypericum extract. J. Geriatr. Psychiatry Neurol., 1994, 7 Suppl 1, S57-59.
20. Cott, J.M. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry, 1997, 30 Suppl 2, 108-112. (Pubitemid 127732307)
21. Chatterjee, S.S.; Bhattacharya, S.K.; Wonnemann, M.; Singer, A.; Muller, W.E. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci., 1998, 63, 499-510. (Pubitemid 28367402)
22. Lenoir, S.; Degenring, F.H.; Saller, R. A double-blind randomised trial to investigate three different concentrations of a standardised fresh plant extract obtained from the shoot tips of Hypericum perforatum L. Phytomedicine, 1999, 6, 141-146. (Pubitemid 129632908)
23. Gurevich, A.I.; Dobrynin, V.N.; Kolosov, M.N.; Popravko, S.A.; Riabova, I.D. Antibiotic hyperforin from Hypericum perforatum L. Antibiotiki., 1971, 16, 510-513.
24. Brondz I, G.T., Groth PA, Aasen AJ. The relative stereochemistry of hyperforin - an antibiotic from Hypericum perforatum L. Tetrahedron Lett., 1982, 23.
25. Brondz I, G.T., Groth PA, Aasen AJ. The absolute configuration of hyperforin, an antibiotic from Hypericum perforatum L., based on the crystal structure determination of its p-bromobenzoate ester. Acta. Chem. Scand., 1983, 37, 263-265.
26. Kraus, G.A.; Dneprovskaia, E.; Nguyen, T.H.; Jeon, I. Synthesis of a model system for the preparation of phloroglucinol containing natural products. Tetrahedron, 2003, 59, 8975-8978. (Pubitemid 37324239)
27. Isacchi, B.; Bergonzi, M.C.; Carnevali, F.; van der Esch, S.A.; Vincieri, F.F.; Bilia, A.R. Analysis and stability of the constituents of St. John's wort oils prepared with different methods. J. Pharm. Biomed. Anal., 2007, 45, 756-761.
28. Wurglics, M.; Westerhoff, K.; Kaunzinger, A.; Wilke, A.; Baumeister, A.; Dressman, J.; Schubert-Zsilavecz, M. Comparison of German St. John's wort products according to hyperforin and total hypericin content. J. Am. Pharm. Assoc. (Wash)., 2001, 41, 560-566.
29. Schulz, H.U.; Schurer, M.; Bassler, D.; Weiser, D. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. ArzneimittelForschung, 2005, 55, 15-22. (Pubitemid 40175249)
30. Schulz, H.U.; Schurer, M.; Bassler, D.; Weiser, D. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers. ArzneimittelForschung, 2005, 55, 561-568. (Pubitemid 41546100)
31. Cui, Y.; Gurley, B.; Ang, C.Y.; Leakey, J. Determination of hyperforin in human plasma using solid-phase extraction and high-performance liquid chromatography with ultraviolet detection. J. Chromatogr., 2002, 780, 129-135.
32. Muller, W.E.; Singer, A.; Wonnemann, M.; Hafner, U.; Rolli, M.; Schafer, C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry, 1998, 31 Suppl 1, 16-21.
33. Laakmann, G.; Schule, C.; Baghai, T.; Kieser, M. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry., 1998, 31 Suppl 1, 54-59.
34. Greeson, J.M.; Sanford, B.; Monti, D.A. St. John's wort (Hypericum perforatum): a review of the current pharmacological, toxicological, and clinical literature. Psychopharmacology, 2001, 153, 402-414.
35. Bhattacharya, S.K.; Chakrabarti, A.; Chatterjee, S.S. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models. Pharmacopsychiatry, 1998, 31 Suppl 1, 22-29.
36. Kaehler, S.T.; Sinner, C.; Chatterjee, S.S.; Philippu, A. Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci. Lett., 1999, 262, 199-202. (Pubitemid 29136804)
37. Dinamarca, M.C.; Cerpa, W.; Garrido, J.; Hancke, J.L.; Inestrosa, N.C. Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. Mol. Psychiatry, 2006, 11, 1032-1048.
38. Dinamarca, M.C.; Arrazola, M.; Toledo, E.; Cerpa, W.F.; Hancke, J.; Inestrosa, N.C. Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chem. Biol. Interact., 2008, 175, 142-149.
39. Cerpa, W., Hancke, J. L., Morazzoni, P., Bombardelli, E., Riva, A., Marin, P. P. and Inestrosa, N. C. The hyperforin derivative IDN5706 occludes spatial memory impairments and neuropathological changes in a double transgenic Alzheimer's mouse model. Curr. Alzheimer Res., 2009, (epub ahead of print).
40. Gobbi, M.; Valle, F.D.; Ciapparelli, C.; Diomede, L.; Morazzoni, P.; Verotta, L.; Caccia, S.; Cervo, L.; Mennini, T. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 360, 262-269. (Pubitemid 29480916)
41. Gobbi, M.; Moia, M.; Pirona, L.; Morizzoni, P.; Mennini, T. In vitro binding studies with two hypericum perforatum extracts-hyperforin, hypericin and biapigenin - on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry, 2001, 34 Suppl 1, S45-48. (Pubitemid 32701739)
42. Singer, A.; Wonnemann, M.; Muller, W.E. Hyperforin, a major antidepressant constituent of St. John's Wort, inhibits serotonin uptake by elevating free intracellular Na+1. J. Pharmacol. Exp. Ther., 1999, 290, 1363-1368.
43. Malandro, M.S.; Kilberg, M.S. Molecular biology of mammalian amino acid transporters. Annu. Rev. Biochem., 1996, 65, 305-336. (Pubitemid 26250612)
44. Frelin, C.; Barbry, P.; Vigne, P.; Chassande, O.; Cragoe, E.J., Jr.; Lazdunski, M. Amiloride and its analogs as tools to inhibit Na+ transport via the Na+ channel, the Na+/H+ antiport and the Na+/Ca2+ exchanger. Biochimie, 1988, 70, 1285-1290.
45. Price, M.P.; Snyder, P.M.; Welsh, M.J. Cloning and expression of a novel human brain Na+ channel. J. Biol. Chem., 1996, 271, 7879-7882.
46. Garcia-Anoveros, J.; Derfler, B.; Neville-Golden, J.; Hyman, B.T.; Corey, D.P. BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 1459-1464.
47. Wonnemann, M.; Singer, A.; Muller, W.E. Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John's Wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology, 2000, 23, 188-197.
48. Roz, N.; Rehavi, M. Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci., 2003, 73, 461-470. (Pubitemid 36577570)
49. Roz, N.; Rehavi, M. Hyperforin depletes synaptic vesicles content and induces compartmental redistribution of nerve ending monoamines. Life Sci., 2004, 75, 2841-2850. (Pubitemid 39349270)
50. Koch, E.; Chatterjee, S.S. Hyperforin stimulates intracellular calcium mobilisation and enhances extracellular acidification in DDT1-MF2 smooth muscle cells. Pharmacopsychiatry, 2001, 34 Suppl 1, S70-73.
51. Marsh, W.L.; Davies, J.A. The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin. Life Sci., 2002, 71, 2645-2655.
52. Tu, P.; Gibon, J.; Bouron, A. The TRPC6 channel activator hyperforin induces the release of zinc and calcium from mitochondria. J. Neurochem., 2009, (epub ahead of print).
53. Chatterjee, S.S.; Biber, A.; Weibezahn, C. Stimulation of glutamate, aspartate and gamma-aminobutyric acid release from synaptosomes by hyperforin. Pharmacopsychiatry, 2001, 34 Suppl 1, S11-19. (Pubitemid 32701733)
54. Chatterjee, S.; Filippov, V.; Lishko, P.; Maximyuk, O.; Noldner, M.; Krishtal, O. Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Sci., 1999, 65, 2395-2405. (Pubitemid 29531042)
55. MacDonald, J.F.; Nowak, L.M. Mechanisms of blockade of excitatory amino acid receptor channels. Trends Pharmacol. Sci., 1990, 11, 167-172. (Pubitemid 20118011)
56. MacDonald, J.F.; Jackson, M.F.; Beazely, M.A. Hippocampal longterm synaptic plasticity and signal amplification of NMDA receptors. Crit. Rev. Neurobiol., 2006, 18, 71-84.
57. Miyamoto, E. Molecular mechanism of neuronal plasticity: induction and maintenance of long-term potentiation in the hippocampus. J. Pharmacol. Sci., 2006, 100, 433-442. (Pubitemid 44609534)
58. Dong, X.X.; Wang, Y.; Qin, Z.H. Molecular mechanisms of excitotoxicity and their relevance to pathogenesis of neurodegenerative diseases. Acta Pharmacol. Sin., 2009, 30, 379-387.
59. Beal, M.F. Role of excitotoxicity in human neurological disease. Curr. Opin. Neurobiol., 1992, 2, 657-662.
60. Stoltenburg-Didinger, G. Neuropathology of the hippocampus and its susceptibility to neurotoxic insult. Neurotoxicology, 1994, 15, 445-450. (Pubitemid 24321234)
61. Chang, Y.C.; Kim, H.W.; Rapoport, S.I.; Rao, J.S. Chronic NMDA administration increases neuroinflammatory markers in rat frontal cortex: cross-talk between excitotoxicity and neuroinflammation. Neurochem. Res., 2008, 33, 2318-2323.
62. Estrada-Sanchez, A.M.; Montiel, T.; Segovia, J.; Massieu, L. Glutamate toxicity in the striatum of the R6/2 Huntington's disease transgenic mice is age-dependent and correlates with decreased levels of glutamate transporters. Neurobiol. Dis., 2009, (epub ahead of print).
63. Lacor, P.N.; Buniel, M.C.; Furlow, P.W.; Clemente, A.S.; Velasco, P.T.; Wood, M.; Viola, K.L.; Klein, W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci., 2007, 27, 796-807.
64. Roselli, F.; Tirard, M.; Lu, J.; Hutzler, P.; Lamberti, P.; Livrea, P.; Morabito, M.; Almeida, O.F. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J. Neurosci., 2005, 25, 11061-11070.
65. Shelat, P.B.; Chalimoniuk, M.; Wang, J.H.; Strosznajder, J.B.; Lee, J.C.; Sun, A.Y.; Simonyi, A.; Sun, G.Y. Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J. Neurochem., 2008, 106, 45-55.
66. Kumar, V.; Mdzinarishvili, A.; Kiewert, C.; Abbruscato, T.; Bickel, U.; van der Schyf, C.J.; Klein, J. NMDA receptorantagonistic properties of hyperforin, a constituent of St. John's Wort. J. Pharmacol. Sci., 2006, 102, 47-54. (Pubitemid 44440966)
67. Weichel, O.; Hilgert, M.; Chatterjee, S.S.; Lehr, M.; Klein, J. Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 360, 609-615.
68. Eckert, G.P.; Muller, W.E. Effects of hyperforin on the fluidity of brain membranes. Pharmacopsychiatry, 2001, 34 Suppl 1, S22-25.
69. Eckert, G.P.; Keller, J.H.; Jourdan, C.; Karas, M.; Volmer, D.A.; Schubert-Zsilavecz, M.; Muller, W.E. Hyperforin modifies neuronal membrane properties in vivo. Neurosci. Lett., 2004, 367, 139-143.
70. Alvarez, A.; Bronfman, F.; Perez, C.A.; Vicente, M.; Garrido, J.; Inestrosa, N.C. Acetylcholinesterase, a senile plaque component, affects the fibrillogenesis of amyloid-beta-peptides. Neurosci. Lett., 1995, 201, 49-52.
71. Inestrosa, N.C.; Alvarez, A.; Perez, C.A.; Moreno, R.D.; Vicente, M.; Linker, C.; Casanueva, O.I.; Soto, C.; Garrido, J. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme. Neuron., 1996, 16, 881-891. (Pubitemid 26124065)
72. Colombres, M.; Sagal, J.P.; Inestrosa, N.C. An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. Curr. Pharma. Des., 2004, 10, 3121-3130.
73. Smith, R.; Chung, H.; Rundquist, S.; Maat-Schieman, M.L.; Colgan, L.; Englund, E.; Liu, Y.J.; Roos, R.A.; Faull, R.L.; Brundin, P.; Li, J.Y. Cholinergic neuronal defect without cell loss in Huntington's disease. Hum. Mol. Genet., 2006, 15, 3119-3131.
74. De Felice, F.G.; Velasco, P.T.; Lambert, M.P.; Viola, K.; Fernandez, S.J.; Ferreira, S.T.; Klein, W.L. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptordependent mechanism that is blocked by the Alzheimer drug memantine. J. Biol. Chem., 2007, 282, 11590-11601.
75. Francis, P.T.; Perry, E.K. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov. Disord., 2007, 22 Suppl 17, S351-357.
76. Gomez-Anson, B.; Alegret, M.; Munoz, E.; Sainz, A.; Monte, G.C.; Tolosa, E. Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology, 2007, 68, 906-910. (Pubitemid 46584537)
77. Griffith, H.R.; Okonkwo, O.C.; O'Brien, T.; Hollander, J.A. Reduced brain glutamate in patients with Parkinson's disease. NMR Biomed., 2008, 21, 381-387. (Pubitemid 351771888)
78. Watkins, R.E.; Maglich, J.M.; Moore, L.B.; Wisely, G.B.; Noble, S.M.; Davis-Searles, P.R.; Lambert, M.H.; Kliewer, S.A.; Redinbo, M.R. 2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry, 2003, 42, 1430-1438.
79. Yang, B.; Ferguson, A.V. Orexin-A depolarizes nucleus tractus solitarius neurons through effects on nonselective cationic and K+ conductances. J. Neurophysiol., 2003, 89, 2167-2175. (Pubitemid 36444269)
80. 2+ inflow in animal cells: a variety of pathways tailored to meet different intracellular Ca2+ signalling requirements. Biochem. J., 1999, 337(Pt 2), 153-169.
81. Smith, S.M.; Bergsman, J.B.; Harata, N.C.; Scheller, R.H.; Tsien, R.W. Recordings from single neocortical nerve terminals reveal a nonselective cation channel activated by decreases in extracellular calcium. Neuron, 2004, 41, 243-256.
82. Latchford, K.J.; Ferguson, A.V. Angiotensin depolarizes parvocellular neurons in paraventricular nucleus through modulation of putative nonselective cationic and potassium conductances. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2005, 289, R52-58.
83. Treiber, K.; Singer, A.; Henke, B.; Muller, W.E. Hyperforin activates nonselective cation channels (NSCCs). Br. J. Pharmacol., 2005, 145, 75-83.
84. Inoue, R.; Okada, T.; Onoue, H.; Hara, Y.; Shimizu, S.; Naitoh, S.; Ito, Y.; Mori, Y. The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel. Cir. Res., 2001, 88, 325-332. (Pubitemid 32173757)
85. Inoue, R.; Jensen, L.J.; Shi, J.; Morita, H.; Nishida, M.; Honda, A.; Ito, Y. Transient receptor potential channels in cardiovascular function and disease. Cir. Res., 2006, 99, 119-131. (Pubitemid 44297035)
86. Nilius, B.; Owsianik, G.; Voets, T.; Peters, J.A. Transient receptor potential cation channels in disease. Physiol. Rev., 2007, 87, 165-217. (Pubitemid 46207713)
87. Liu, D.; Zhu, Z.; Tepel, M. The role of transient receptor potential channels in metabolic syndrome. Hypertens Res., 2008, 31, 1989-1995.
88. Montell, C.; Birnbaumer, L.; Flockerzi, V.; Bindels, R.J.; Bruford, E.A.; Caterina, M.J.; Clapham, D.E.; Harteneck, C.; Heller, S.; Julius, D.; Kojima, I.; Mori, Y.; Penner, R.; Prawitt, D.; Scharenberg, A.M.; Schultz, G.; Shimizu, N.; Zhu, M.X. A unified nomenclature for the superfamily of TRP cation channels. Mol. Cell., 2002, 9, 229-231. (Pubitemid 34195549)
89. Clapham, D.E. TRP channels as cellular sensors. Nature., 2003, 426, 517-524.
90. Moran, M.M.; Xu, H.; Clapham, D.E. TRP ion channels in the nervous system. Curr. Opin. Neurobiol., 2004, 14, 362-369.
91. Boulay, G.; Zhu, X.; Peyton, M.; Jiang, M.; Hurst, R.; Stefani, E.; Birnbaumer, L. Cloning and expression of a novel mammalian homolog of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the Gq class of G protein. J. Biol. Chem., 1997, 272, 29672-29680. (Pubitemid 27508059)
92. Otsuka, Y.; Sakagami, H.; Owada, Y.; Kondo, H. Differential localization of mRNAs for mammalian trps, presumptive capacitative calcium entry channels, in the adult mouse brain. Tohoku J. Exp. Med., 1998, 185, 139-146. (Pubitemid 128473295)
93. Bonaventure, P.; Guo, H.; Tian, B.; Liu, X.; Bittner, A.; Roland, B.; Salunga, R.; Ma, X.J.; Kamme, F.; Meurers, B.; Bakker, M.; Jurzak, M.; Leysen, J.E.; Erlander, M.G. Nuclei and subnuclei gene expression profiling in mammalian brain. Brain Res., 2002, 943, 38-47. (Pubitemid 34671172)
94. Chung, Y.H.; Sun Ahn, H.; Kim, D.; Hoon Shin, D.; Su Kim, S.; Yong Kim, K.; Bok Lee, W.; Ik Cha, C. Immunohistochemical study on the distribution of TRPC channels in the rat hippocampus. Brain Res., 2006, 1085, 132-137. (Pubitemid 43728203)
95. Venkatachalam, K.; Montell, C. TRP channels. Anun. Rev. Biochem., 2007, 76, 387-417.
96. Hofmann, T.; Obukhov, A.G.; Schaefer, M.; Harteneck, C.; Gudermann, T.; Schultz, G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature., 1999, 397, 259-263. (Pubitemid 29051175)
97. Zhou, J.; Du, W.; Zhou, K.; Tai, Y.; Yao, H.; Jia, Y.; Ding, Y.; Wang, Y. Critical role of TRPC6 channels in the formation of excitatory synapses. Nat. Neurosci., 2008, 11, 741-743. (Pubitemid 351896670)
98. Perez-Garcia, M.J.; Gou-Fabregas, M.; de Pablo, Y.; Llovera, M.; Comella, J.X.; Soler, R.M. Neuroprotection by neurotrophic factors and membrane depolarization is regulated by calmodulin kinase IV. J. Biol. Chem., 2008, 283, 4133-4144.
99. Fukushima, H.; Maeda, R.; Suzuki, R.; Suzuki, A.; Nomoto, M.; Toyoda, H.; Wu, L.J.; Xu, H.; Zhao, M.G.; Ueda, K.; Kitamoto, A.; Mamiya, N.; Yoshida, T.; Homma, S.; Masushige, S.; Zhuo, M.; Kida, S. Upregulation of calcium/calmodulin-dependent protein kinase IV improves memory formation and rescues memory loss with aging. J. Neurosci., 2008, 28, 9910-9919.
100. Tai, Y.; Feng, S.; Ge, R.; Du, W.; Zhang, X.; He, Z.; Wang, Y. TRPC6 channels promote dendritic growth via the CaMKIV-CREB pathway. J. Cell Sci., 2008, 121, 2301-2307.
101. Li, Y.; Jia, Y.C.; Cui, K.; Li, N.; Zheng, Z.Y.; Wang, Y.Z.; Yuan, X.B. Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. Nature, 2005, 434, 894-898.
102. Jung, S.; Muhle, A.; Schaefer, M.; Strotmann, R.; Schultz, G.; Plant, T.D. Lanthanides potentiate TRPC5 currents by an action at extracellular sites close to the pore mouth. J. Biol. Chem., 2003, 278, 3562-3571.
103. Leuner, K.; Kazanski, V.; Muller, M.; Essin, K.; Henke, B.; Gollasch, M.; Harteneck, C.; Muller, W.E. Hyperforin - a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J., 2007, 21, 4101-4111.
104. Vorbach, E.U.; Arnoldt, K.H.; Wolpert, E. St John's wort: a potential therapy for elderly depressed patients? Drugs Aging, 2000, 16, 189-197. (Pubitemid 30166920)
105. Roz, N.; Mazur, Y.; Hirshfeld, A.; Rehavi, M. Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci., 2002, 71, 2227-2237.
106. Kumar, V.; Singh, P.N.; Muruganandam, A.V.; Bhattacharya, S.K. Effect of Indian Hypericum perforatum Linn on animal models of cognitive dysfunction. J. Ethnopharmacol., 2000, 72, 119-128.
107. Spignoli, G.; Pepeu, G. Interactions between oxiracetam, aniracetam and scopolamine on behavior and brain acetylcholine. Pharmacol. Biochem. Behav., 1987, 27, 491-495. (Pubitemid 17107019)
108. Khalifa, A.E. Hypericum perforatum as a nootropic drug: enhancement of retrieval memory of a passive avoidance conditioning paradigm in mice. J. Ethnopharmacol., 2001, 76, 49-57.
109. Klusa, V.; Germane, S.; Noldner, M.; Chatterjee, S.S. Hypericum extract and hyperforin: memory-enhancing properties in rodents. Pharmacopsychiatry, 2001, 34 Suppl 1, S61-69.
110. Cassel, J.C.; Mathis, C.; Majchrzak, M.; Moreau, P.H.; Dalrymple-Alford, J.C. Coexisting cholinergic and parahippocampal degeneration: a key to memory loss in dementia and a challenge for transgenic models? Neurodegen. Dis., 2008, 5, 304-317.
111. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766.
112. Morgan, C.; Colombres, M.; Nunez, M.T.; Inestrosa, N.C. Structure and function of amyloid in Alzheimer's disease. Prog. Neurobiol., 2004, 74, 323-349.
113. Klein, W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int., 2002, 41, 345-352.
114. Duyckaerts, C.; Potier, M.C.; Delatour, B. Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol., 2008, 115, 5-38. (Pubitemid 50005258)
115. Soto, C.; Branes, M.C.; Alvarez, J.; Inestrosa, N.C. Structural determinants of the Alzheimer's amyloid beta-peptide. J. Neurochem., 1994, 63, 1191-1198.
116. Sandbrink, R.; Masters, C.L.; Beyreuther, K. APP gene family: unique age-associated changes in splicing of Alzheimer's betaA4-amyloid protein precursor. Neurobiol. Dis., 1994, 1, 13-24. (Pubitemid 124002847)
117. Li, H.; Wolfe, M.S.; Selkoe, D.J. Toward structural elucidation of the gamma-secretase complex. Structure, 2009, 17, 326-334.
118. Bandyopadhyay, S.; Goldstein, L.E.; Lahiri, D.K.; Rogers, J.T. Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease. Curr. Med. Chem., 2007, 14, 2848-2864.
119. Fahrenholz, F. Alpha-secretase as a therapeutic target. Curr. Alzheimer Res., 2007, 4, 412-417.
120. Gakhar-Koppole, N.; Hundeshagen, P.; Mandl, C.; Weyer, S.W.; Allinquant, B.; Muller, U.; Ciccolini, F. Activity requires soluble amyloid precursor protein alpha to promote neurite outgrowth in neural stem cell-derived neurons via activation of the MAPK pathway. Eur. J Neurosci., 2008, 28, 871-882.
121. Mbebi, C.; See, V.; Mercken, L.; Pradier, L.; Muller, U.; Loeffler, J.P. Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway. J . Biol. Chem., 2002, 277, 20979-20990.
122. Bastianetto, S.; Krantic, S.; Quirion, R. Polyphenols as potential inhibitors of amyloid aggregation and toxicity: possible significance to Alzheimer's disease. Mini Rev. Med. Chem., 2008, 8, 429-435.
123. Wisniewski, T.; Sadowski, M. Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC Neurosci., 2008, 9 Suppl 2, S5.
124. Zhao, B. Natural antioxidants protect neurons in Alzheimer's disease and Parkinson's disease. Neurochem. Res., 2009, 34, 630-638.
125. Giunta, B.; Fernandez, F.; Nikolic, W.V.; Obregon, D.; Rrapo, E.; Town, T.; Tan, J. Inflammaging as a prodrome to Alzheimer's disease. J. Neuroinflammation, 2008, 5, 51.
126. Pellistri, F.; Bucciantini, M.; Relini, A.; Nosi, D.; Gliozzi, A.; Robello, M.; Stefani, M. Nonspecific interaction of prefibrillar amyloid aggregates with glutamatergic receptors results in Ca2+ increase in primary neuronal cells. J. Biol. Chem., 2008, 283, 29950-29960.
127. Clerici, F.; Vanacore, N.; Elia, A.; Spila-Alegiani, S.; Pomati, S.; Da Cas, R.; Raschetti, R.; Mariani, C. Memantine in moderatelysevere-to-severe Alzheimer's disease: a postmarketing surveillance study. Drugs Aging., 2009, 26, 321-332.
128. Bronfman, F.C.; Garrido, J.; Alvarez, A.; Morgan, C.; Inestrosa, N.C. Laminin inhibits amyloid-beta-peptide fibrillation. Neurosci. Lett., 1996, 218, 201-203.
129. Morgan, C.; Bugueno, M.P.; Garrido, J.; Inestrosa, N.C. Laminin affects polymerization, depolymerization and neurotoxicity of Abeta peptide. Peptides., 2002, 23, 1229-1240.
130. Pappolla, M.; Bozner, P.; Soto, C.; Shao, H.; Robakis, N.K.; Zagorski, M.; Frangione, B.; Ghiso, J. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J. Biol. Chem., 1998, 273, 7185-7188.
131. Ono, K.; Hasegawa, K.; Yoshiike, Y.; Takashima, A.; Yamada, M.; Naiki, H. Nordihydroguaiaretic acid potently breaks down preformed Alzheimer's beta-amyloid fibrils in vitro. J. Neurochem., 2002, 81, 434-440. (Pubitemid 34809322)
132. Ono, K.; Yoshiike, Y.; Takashima, A.; Hasegawa, K.; Naiki, H.; Yamada, M. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J. Neurochem., 2003, 87, 172-181. (Pubitemid 37210651)
133. Solomon, B.; Koppel, R.; Frankel, D.; Hanan-Aharon, E. Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 4109-4112. (Pubitemid 27180507)
134. Fraser, P.E.; Nguyen, J.T.; McLachlan, D.R.; Abraham, C.R.; Kirschner, D.A. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem., 1993, 61, 298-305.
135. Luo, Y.; Smith, J.V.; Paramasivam, V.; Burdick, A.; Curry, K.J.; Buford, J.P.; Khan, I.; Netzer, W.J.; Xu, H.; Butko, P. Inhibition of amyloid-beta aggregation and caspase-3 activation by the Ginkgo biloba extract EGb761. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 12197-12202.
136. Kiuchi, Y.; Isobe, Y.; Fukushima, K. Type IV collagen prevents amyloid beta-protein fibril formation. Life Sci., 2002, 70, 1555-1564. (Pubitemid 34164549)
137. Chacon, M.A.; Barria, M.I.; Soto, C.; Inestrosa, N.C. Beta-sheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol. Psychiatry., 2004, 9, 953-961.
138. Ono, K.; Condron, M.M.; Teplow, D.B. Structure-neurotoxicity relationships of amyloid beta-protein oligomers. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 14745-14750.
139. Cerpa, W.; Dinamarca, M.C.; Inestrosa, N.C. Structure-function implications in Alzheimer's disease: effect of Abeta oligomers at central synapses. Curr. Alzheimer Res., 2008, 5, 233-243.
140. Giuffrida, M.L.; Caraci, F.; Pignataro, B.; Cataldo, S.; De Bona, P.; Bruno, V.; Molinaro, G.; Pappalardo, G.; Messina, A.; Palmigiano, A.; Garozzo, D.; Nicoletti, F.; Rizzarelli, E.; Copani, A. Betaamyloid monomers are neuroprotective. J. Neurosci., 2009, 29, 10582-10587.
141. Rozio, M.; Fracasso, C.; Riva, A.; Morazzoni, P.; Caccia, S. Highperformance liquid chromatography measurement of hyperforin and its reduced derivatives in rodent plasma. J. Chromatogr., 2005, 816, 21-27. (Pubitemid 40143485)
142. Harper, J.D.; Lansbury, P.T., Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem., 1997, 66, 385-407.
143. Inestrosa, N.C.; Perelman, A. Distribution and anchoring of molecular forms of acetylcholinesterase. Trends Pharmacol. Sci., 1989, 10, 325-329.
144. Inestrosa, N.C.; Alvarez, A.; Calderon, F. Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid betapeptide into Alzheimer's filaments. Mol. Psychiatry, 1996, 1, 359-361.
145. Chacon, M.A.; Reyes, A.E.; Inestrosa, N.C. Acetylcholinesterase induces neuronal cell loss, astrocyte hypertrophy and behavioral deficits in mammalian hippocampus. J. Neurochem., 2003, 87, 195-204.
146. Reyes, A.E.; Chacon, M.A.; Dinamarca, M.C.; Cerpa, W.; Morgan, C.; Inestrosa, N.C. Acetylcholinesterase-Abeta complexes are more toxic than Abeta fibrils in rat hippocampus: effect on rat betaamyloid aggregation, laminin expression, reactive astrocytosis, and neuronal cell loss. Am. J. Pathol., 2004, 164, 2163-2174.
147. Buchholzer, M.L.; Dvorak, C.; Chatterjee, S.S.; Klein, J. Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John's wort. J. Pharmacol. Exp. Ther., 2002, 301, 714-719. (Pubitemid 34429988)
148. Kiewert, C.; Buchholzer, M.L.; Hartmann, J.; Chatterjee, S.S.; Klein, J. Stimulation of hippocampal acetylcholine release by hyperforin, a constituent of St. John's Wort. Neurosci. Lett., 2004, 364, 195-198. (Pubitemid 38757931)
149. Miranda, S.; Opazo, C.; Larrondo, L.F.; Munoz, F.J.; Ruiz, F.; Leighton, F.; Inestrosa, N.C. The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog. Neurobiol., 2000, 62, 633-648.
150. Hunt, E.J.; Lester, C.E.; Lester, E.A.; Tackett, R.L. Effect of St. John's wort on free radical production. Life Sci., 2001, 69, 181-190. (Pubitemid 32523074)
151. Albert, D.; Zundorf, I.; Dingermann, T.; Muller, W.E.; Steinhilber, D.; Werz, O. Hyperforin is a dual inhibitor of cyclooxygenase-1 and 5-lipoxygenase. Biochem. Pharmacol., 2002, 64, 1767-1775. (Pubitemid 35355728)
152. Feisst, C.; Albert, D.; Verotta, L.; Werz, O. Evaluation of hyperforin analogues for inhibition of 5-lipoxygenase. Med. Chem. (Shariqah (United Arab Emirates))., 2005, 1, 287-291.
153. Feisst, C.; Pergola, C.; Rakonjac, M.; Rossi, A.; Koeberle, A.; Dodt, G.; Hoffmann, M.; Hoernig, C.; Fischer, L.; Steinhilber, D.; Franke, L.; Schneider, G.; Radmark, O.; Sautebin, L.; Werz, O. Hyperforin is a novel type of
154. Feisst, C.; Werz, O. Suppression of receptor-mediated Ca2+ mobilization and functional leukocyte responses by hyperforin. Biochem. Pharmacol., 2004, 67, 1531-1539. (Pubitemid 38388215)
155. Heilmann, J.; Winkelmann, K.; Sticher, O. Studies on the antioxidative activity of phloroglucinol derivatives isolated from hypericum species. Planta med., 2003, 69, 202-206. (Pubitemid 36470122)
156. Pike, C.J.; Cummings, B.J.; Cotman, C.W. Early association of reactive astrocytes with senile plaques in Alzheimer's disease. Exp. Neurol., 1995, 132, 172-179.
157. McGeer, P.L.; Itagaki, S.; Tago, H.; McGeer, E.G. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci. Lett., 1987, 79, 195-200.
158. Butterfield, D.A. Amyloid beta-peptide [1-42]-associated free radical-induced oxidative stress and neurodegeneration in Alzheimer's disease brain: mechanisms and consequences. Curr. Med. Chem., 2003, 10, 2651-2659.
159. Verotta, L.; Appendino, G.; Jakupovic, J.; Bombardelli, E. Hyperforin analogues from St. John's wort (Hypericum perforatum). J. natural products., 2000, 63, 412-415. (Pubitemid 30173710)
160. Verotta, L.; Appendino, G.; Belloro, E.; Bianchi, F.; Sterner, O.; Lovati, M.; Bombardelli, E. Synthesis and biological evaluation of hyperforin analogues. Part I. Modification of the enolized cyclohexanedione moiety. J. Nat. Prod., 2002, 65, 433-438.
161. Cummings, B.J.; Su, J.H.; Cotman, C.W. Neuritic involvement within bFGF immunopositive plaques of Alzheimer's disease. Exp. Neurol., 1993, 124, 315-325. (Pubitemid 24041779)
162. Nielsen, E.H.; Nybo, M.; Svehag, S.E. Electron microscopy of prefibrillar structures and amyloid fibrils. Methods Enzymol., 1999, 309, 491-496. (Pubitemid 29446468)
163. Froestl, B.; Steiner, B.; Muller, W.E. Enhancement of proteolytic processing of the beta-amyloid precursor protein by hyperforin. Biochem. Pharmacol., 2003, 66, 2177-2184. (Pubitemid 37377862)
164. Qin, W.; Ho, L.; Pompl, P.N.; Peng, Y.; Zhao, Z.; Xiang, Z.; Robakis, N.K.; Shioi, J.; Suh, J.; Pasinetti, G.M. Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J. Biol. Chem., 2003, 278, 50970-50977.
165. Dash, P.K.; Moore, A.N. Enhanced processing of APP induced by IL-1 beta can be reduced by indomethacin and nordihydroguaiaretic acid. Biochem. Biophys. Res. Commun., 1995, 208, 542-548.
166. Beerhues, L. Hyperforin. Phytochemistry, 2006, 67, 2201-2207.
167. Gomez-Isla, T.; Hollister, R.; West, H.; Mui, S.; Growdon, J.H.; Petersen, R.C.; Parisi, J.E.; Hyman, B.T. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol., 1997, 41, 17-24. (Pubitemid 27057088)
168. Regeur, L.; Jensen, G.B.; Pakkenberg, H.; Evans, S.M.; Pakkenberg, B. No global neocortical nerve cell loss in brains from patients with senile dementia of Alzheimer's type. Neurobiol. Aging., 1994, 15, 347-352.
169. Irizarry, M.C.; Soriano, F.; McNamara, M.; Page, K.J.; Schenk, D.; Games, D.; Hyman, B.T. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci., 1997, 17, 7053-7059.
170. Urbanc, B.; Cruz, L.; Le, R.; Sanders, J.; Ashe, K.H.; Duff, K.; Stanley, H.E.; Irizarry, M.C.; Hyman, B.T. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA., 2002, 99, 13990-13995.
171. Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods., 1984, 11, 47-60. (Pubitemid 14088970)
172. Morris, R.G. Episodic-like memory in animals: psychological criteria, neural mechanisms and the value of episodic-like tasks to investigate animal models of neurodegenerative disease. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 2001, 356, 1453-1465.
173. Lessard, C.B.; Lussier, M.P.; Cayouette, S.; Bourque, G.; Boulay, G. The overexpression of presenilin2 and Alzheimer's-diseaselinked presenilin2 variants influences TRPC6-enhanced Ca2+ entry into HEK293 cells. Cell. Signal., 2005, 17, 437-445. (Pubitemid 39643062)
174. Turner, P.R.; O'Connor, K.; Tate, W.P.; Abraham, W.C. Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory. Prog. Neurobiol., 2003, 70, 1-32.
175. Thornton, E.; Vink, R.; Blumbergs, P.C.; Van Den Heuvel, C. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. Brain Res., 2006, 1094, 38-46. (Pubitemid 43927608)